Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
4,973
archived clinical trials in
High Cholesterol

Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1)
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab in Patients With Primary Hypercholesterolemia
Status: Enrolling
Updated:  10/24/2013
Clinical Research Facility
mi
from
Kenosha, WI
Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1)
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab in Patients With Primary Hypercholesterolemia
Status: Enrolling
Updated: 10/24/2013
Clinical Research Facility
mi
from
Kenosha, WI
Click here to add this to my saved trials
Effects of Niacin On Fatty Acid Trapping
Effect of Niacin On Fatty Acid Trapping
Status: Enrolling
Updated:  11/7/2013
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Effects of Niacin On Fatty Acid Trapping
Effect of Niacin On Fatty Acid Trapping
Status: Enrolling
Updated: 11/7/2013
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Effects of Niacin On Fatty Acid Trapping
Effect of Niacin On Fatty Acid Trapping
Status: Enrolling
Updated:  11/7/2013
Presbyterian Hospital
mi
from
Philadelphia, PA
Effects of Niacin On Fatty Acid Trapping
Effect of Niacin On Fatty Acid Trapping
Status: Enrolling
Updated: 11/7/2013
Presbyterian Hospital
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Characterization of Dyslipidemia in Adolescent Obesity
Characterization of Dyslipidemia in Adolescent Obesity
Status: Enrolling
Updated:  11/13/2013
The Center For Nutrition and Preventive Medicine
mi
from
Charlotte, NC
Characterization of Dyslipidemia in Adolescent Obesity
Characterization of Dyslipidemia in Adolescent Obesity
Status: Enrolling
Updated: 11/13/2013
The Center For Nutrition and Preventive Medicine
mi
from
Charlotte, NC
Click here to add this to my saved trials
Study of Changes in Total Cholesterol Levels as a Function of Consuming a Supplement Designed to Improve Cardiovascular Health
A Double-blinded, Placebo-controlled Randomized Trial Assessing the Extent to Which Consumption of Two Different Amounts of a Non-Pharmaceutical Food Supplement Can Improve Cardiovascular Health
Status: Enrolling
Updated:  11/21/2013
Integrative Health Technologies
mi
from
San Antonio, TX
Study of Changes in Total Cholesterol Levels as a Function of Consuming a Supplement Designed to Improve Cardiovascular Health
A Double-blinded, Placebo-controlled Randomized Trial Assessing the Extent to Which Consumption of Two Different Amounts of a Non-Pharmaceutical Food Supplement Can Improve Cardiovascular Health
Status: Enrolling
Updated: 11/21/2013
Integrative Health Technologies
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Study of LY3015014 in Participants With High Cholesterol
A Phase 2 Efficacy and Safety Dose-Ranging Study of LY3015014 in Patients With Primary Hypercholesterolemia
Status: Enrolling
Updated:  12/17/2013
Clinical Research Facility
mi
from
Encino, CA
A Study of LY3015014 in Participants With High Cholesterol
A Phase 2 Efficacy and Safety Dose-Ranging Study of LY3015014 in Patients With Primary Hypercholesterolemia
Status: Enrolling
Updated: 12/17/2013
Clinical Research Facility
mi
from
Encino, CA
Click here to add this to my saved trials
A Study of LY3015014 in Participants With High Cholesterol
A Phase 2 Efficacy and Safety Dose-Ranging Study of LY3015014 in Patients With Primary Hypercholesterolemia
Status: Enrolling
Updated:  12/17/2013
Clinical Research Facility
mi
from
Lancaster, CA
A Study of LY3015014 in Participants With High Cholesterol
A Phase 2 Efficacy and Safety Dose-Ranging Study of LY3015014 in Patients With Primary Hypercholesterolemia
Status: Enrolling
Updated: 12/17/2013
Clinical Research Facility
mi
from
Lancaster, CA
Click here to add this to my saved trials
A Study of LY3015014 in Participants With High Cholesterol
A Phase 2 Efficacy and Safety Dose-Ranging Study of LY3015014 in Patients With Primary Hypercholesterolemia
Status: Enrolling
Updated:  12/17/2013
Clinical Research Facility
mi
from
Spring Valley, CA
A Study of LY3015014 in Participants With High Cholesterol
A Phase 2 Efficacy and Safety Dose-Ranging Study of LY3015014 in Patients With Primary Hypercholesterolemia
Status: Enrolling
Updated: 12/17/2013
Clinical Research Facility
mi
from
Spring Valley, CA
Click here to add this to my saved trials
A Study of LY3015014 in Participants With High Cholesterol
A Phase 2 Efficacy and Safety Dose-Ranging Study of LY3015014 in Patients With Primary Hypercholesterolemia
Status: Enrolling
Updated:  12/17/2013
Clinical Research Facility
mi
from
Aurora, CO
A Study of LY3015014 in Participants With High Cholesterol
A Phase 2 Efficacy and Safety Dose-Ranging Study of LY3015014 in Patients With Primary Hypercholesterolemia
Status: Enrolling
Updated: 12/17/2013
Clinical Research Facility
mi
from
Aurora, CO
Click here to add this to my saved trials
A Study of LY3015014 in Participants With High Cholesterol
A Phase 2 Efficacy and Safety Dose-Ranging Study of LY3015014 in Patients With Primary Hypercholesterolemia
Status: Enrolling
Updated:  12/17/2013
Clinical Research Facility
mi
from
Safety Harbor, FL
A Study of LY3015014 in Participants With High Cholesterol
A Phase 2 Efficacy and Safety Dose-Ranging Study of LY3015014 in Patients With Primary Hypercholesterolemia
Status: Enrolling
Updated: 12/17/2013
Clinical Research Facility
mi
from
Safety Harbor, FL
Click here to add this to my saved trials
A Study of LY3015014 in Participants With High Cholesterol
A Phase 2 Efficacy and Safety Dose-Ranging Study of LY3015014 in Patients With Primary Hypercholesterolemia
Status: Enrolling
Updated:  12/17/2013
Clinical Research Facility
mi
from
Tampa, FL
A Study of LY3015014 in Participants With High Cholesterol
A Phase 2 Efficacy and Safety Dose-Ranging Study of LY3015014 in Patients With Primary Hypercholesterolemia
Status: Enrolling
Updated: 12/17/2013
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
A Study of LY3015014 in Participants With High Cholesterol
A Phase 2 Efficacy and Safety Dose-Ranging Study of LY3015014 in Patients With Primary Hypercholesterolemia
Status: Enrolling
Updated:  12/17/2013
Clinical Research Facility
mi
from
Indianapolis, IN
A Study of LY3015014 in Participants With High Cholesterol
A Phase 2 Efficacy and Safety Dose-Ranging Study of LY3015014 in Patients With Primary Hypercholesterolemia
Status: Enrolling
Updated: 12/17/2013
Clinical Research Facility
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Study of LY3015014 in Participants With High Cholesterol
A Phase 2 Efficacy and Safety Dose-Ranging Study of LY3015014 in Patients With Primary Hypercholesterolemia
Status: Enrolling
Updated:  12/17/2013
Clinical Research Facility
mi
from
Iowa City, IA
A Study of LY3015014 in Participants With High Cholesterol
A Phase 2 Efficacy and Safety Dose-Ranging Study of LY3015014 in Patients With Primary Hypercholesterolemia
Status: Enrolling
Updated: 12/17/2013
Clinical Research Facility
mi
from
Iowa City, IA
Click here to add this to my saved trials
A Study of LY3015014 in Participants With High Cholesterol
A Phase 2 Efficacy and Safety Dose-Ranging Study of LY3015014 in Patients With Primary Hypercholesterolemia
Status: Enrolling
Updated:  12/17/2013
Clinical Research Facility
mi
from
Louisville, KY
A Study of LY3015014 in Participants With High Cholesterol
A Phase 2 Efficacy and Safety Dose-Ranging Study of LY3015014 in Patients With Primary Hypercholesterolemia
Status: Enrolling
Updated: 12/17/2013
Clinical Research Facility
mi
from
Louisville, KY
Click here to add this to my saved trials
A Study of LY3015014 in Participants With High Cholesterol
A Phase 2 Efficacy and Safety Dose-Ranging Study of LY3015014 in Patients With Primary Hypercholesterolemia
Status: Enrolling
Updated:  12/17/2013
Clinical Research Facility
mi
from
Bossier, LA
A Study of LY3015014 in Participants With High Cholesterol
A Phase 2 Efficacy and Safety Dose-Ranging Study of LY3015014 in Patients With Primary Hypercholesterolemia
Status: Enrolling
Updated: 12/17/2013
Clinical Research Facility
mi
from
Bossier, LA
Click here to add this to my saved trials
A Study of LY3015014 in Participants With High Cholesterol
A Phase 2 Efficacy and Safety Dose-Ranging Study of LY3015014 in Patients With Primary Hypercholesterolemia
Status: Enrolling
Updated:  12/17/2013
Clinical Research Facility
mi
from
Charlotte, NC
A Study of LY3015014 in Participants With High Cholesterol
A Phase 2 Efficacy and Safety Dose-Ranging Study of LY3015014 in Patients With Primary Hypercholesterolemia
Status: Enrolling
Updated: 12/17/2013
Clinical Research Facility
mi
from
Charlotte, NC
Click here to add this to my saved trials
A Study of LY3015014 in Participants With High Cholesterol
A Phase 2 Efficacy and Safety Dose-Ranging Study of LY3015014 in Patients With Primary Hypercholesterolemia
Status: Enrolling
Updated:  12/17/2013
Clinical Research Facility
mi
from
Raleigh, NC
A Study of LY3015014 in Participants With High Cholesterol
A Phase 2 Efficacy and Safety Dose-Ranging Study of LY3015014 in Patients With Primary Hypercholesterolemia
Status: Enrolling
Updated: 12/17/2013
Clinical Research Facility
mi
from
Raleigh, NC
Click here to add this to my saved trials
A Study of LY3015014 in Participants With High Cholesterol
A Phase 2 Efficacy and Safety Dose-Ranging Study of LY3015014 in Patients With Primary Hypercholesterolemia
Status: Enrolling
Updated:  12/17/2013
Clinical Research Facility
mi
from
Cincinnati, OH
A Study of LY3015014 in Participants With High Cholesterol
A Phase 2 Efficacy and Safety Dose-Ranging Study of LY3015014 in Patients With Primary Hypercholesterolemia
Status: Enrolling
Updated: 12/17/2013
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Study of LY3015014 in Participants With High Cholesterol
A Phase 2 Efficacy and Safety Dose-Ranging Study of LY3015014 in Patients With Primary Hypercholesterolemia
Status: Enrolling
Updated:  12/17/2013
Clinical Research Facility
mi
from
Toledo, OH
A Study of LY3015014 in Participants With High Cholesterol
A Phase 2 Efficacy and Safety Dose-Ranging Study of LY3015014 in Patients With Primary Hypercholesterolemia
Status: Enrolling
Updated: 12/17/2013
Clinical Research Facility
mi
from
Toledo, OH
Click here to add this to my saved trials
A Study of LY3015014 in Participants With High Cholesterol
A Phase 2 Efficacy and Safety Dose-Ranging Study of LY3015014 in Patients With Primary Hypercholesterolemia
Status: Enrolling
Updated:  12/17/2013
Clinical Research Facility
mi
from
Knoxville, TN
A Study of LY3015014 in Participants With High Cholesterol
A Phase 2 Efficacy and Safety Dose-Ranging Study of LY3015014 in Patients With Primary Hypercholesterolemia
Status: Enrolling
Updated: 12/17/2013
Clinical Research Facility
mi
from
Knoxville, TN
Click here to add this to my saved trials
Cardiovascular Intervention Improvement Telemedicine Study
Cardiovascular Intervention Improvement Telemedicine Study
Status: Enrolling
Updated:  1/17/2014
Durham VA Medical Center
mi
from
Durham, NC
Cardiovascular Intervention Improvement Telemedicine Study
Cardiovascular Intervention Improvement Telemedicine Study
Status: Enrolling
Updated: 1/17/2014
Durham VA Medical Center
mi
from
Durham, NC
Click here to add this to my saved trials
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  1/22/2014
Clinical Research Facility
mi
from
Brimingham, AL
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 1/22/2014
Clinical Research Facility
mi
from
Brimingham, AL
Click here to add this to my saved trials
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  1/22/2014
Clinical Research Facility
mi
from
Good Year, AZ
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 1/22/2014
Clinical Research Facility
mi
from
Good Year, AZ
Click here to add this to my saved trials
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  1/22/2014
Clinical Research Facility
mi
from
Lomita, CA
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 1/22/2014
Clinical Research Facility
mi
from
Lomita, CA
Click here to add this to my saved trials
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  1/22/2014
Clinical Research Facility
mi
from
Rancho Cucamong, CA
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 1/22/2014
Clinical Research Facility
mi
from
Rancho Cucamong, CA
Click here to add this to my saved trials
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  1/22/2014
Clinical Research Facility
mi
from
Cooper City, FL
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 1/22/2014
Clinical Research Facility
mi
from
Cooper City, FL
Click here to add this to my saved trials
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  1/22/2014
Clinical Research Facility
mi
from
Doral, FL
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 1/22/2014
Clinical Research Facility
mi
from
Doral, FL
Click here to add this to my saved trials
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  1/22/2014
Clinical Research Facility
mi
from
Fort Lauderdale, FL
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 1/22/2014
Clinical Research Facility
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  1/22/2014
Clinical Research Facility
mi
from
Ft. Lauderdale, FL
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 1/22/2014
Clinical Research Facility
mi
from
Ft. Lauderdale, FL
Click here to add this to my saved trials
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  1/22/2014
Clinical Research Facility
mi
from
Miami, FL
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 1/22/2014
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  1/22/2014
Clinical Research Facility
mi
from
Miami, FL
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 1/22/2014
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  1/22/2014
Clinical Research Facility
mi
from
Opa Locka, FL
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 1/22/2014
Clinical Research Facility
mi
from
Opa Locka, FL
Click here to add this to my saved trials
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  1/22/2014
Clinical Research Facility
mi
from
Chicago, IL
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 1/22/2014
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  1/22/2014
Clinical Research Facility
mi
from
Indianapolis, IN
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 1/22/2014
Clinical Research Facility
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  1/22/2014
Clinical Research Facility
mi
from
Oxon Hill, MD
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 1/22/2014
Clinical Research Facility
mi
from
Oxon Hill, MD
Click here to add this to my saved trials
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  1/22/2014
Clinical Research Facility
mi
from
Detroit, MI
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 1/22/2014
Clinical Research Facility
mi
from
Detroit, MI
Click here to add this to my saved trials
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  1/22/2014
Clinical Research Facility
mi
from
Linden, NJ
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 1/22/2014
Clinical Research Facility
mi
from
Linden, NJ
Click here to add this to my saved trials
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  1/22/2014
Clinical Research Facility
mi
from
Wall, NJ
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 1/22/2014
Clinical Research Facility
mi
from
Wall, NJ
Click here to add this to my saved trials
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  1/22/2014
Clinical Research Facility
mi
from
Charlotte, NC
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 1/22/2014
Clinical Research Facility
mi
from
Charlotte, NC
Click here to add this to my saved trials
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  1/22/2014
Clinical Research Facility
mi
from
Raleigh, NC
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 1/22/2014
Clinical Research Facility
mi
from
Raleigh, NC
Click here to add this to my saved trials
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  1/22/2014
Clinical Research Facility
mi
from
Akron, OH
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 1/22/2014
Clinical Research Facility
mi
from
Akron, OH
Click here to add this to my saved trials
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  1/22/2014
Clinical Research Facility
mi
from
Cincinnati, OH
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 1/22/2014
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  1/22/2014
Clinical Research Facility
mi
from
Columbus, OH
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 1/22/2014
Clinical Research Facility
mi
from
Columbus, OH
Click here to add this to my saved trials
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  1/22/2014
Clinical Research Facility
mi
from
Toledo, OH
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 1/22/2014
Clinical Research Facility
mi
from
Toledo, OH
Click here to add this to my saved trials
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  1/22/2014
Clinical Research Facility
mi
from
Philadelphia, PA
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 1/22/2014
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  1/22/2014
Clinical Research Facility
mi
from
Pittsburgh, PA
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 1/22/2014
Clinical Research Facility
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  1/22/2014
Clinical Research Facility
mi
from
Simpsonville, SC
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 1/22/2014
Clinical Research Facility
mi
from
Simpsonville, SC
Click here to add this to my saved trials
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated:  1/22/2014
Clinical Research Facility
mi
from
Dallas, TX
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021 AM1)
A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C
Status: Enrolling
Updated: 1/22/2014
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Efficacy and Tolerability of Anacetrapib Added to Ongoing Lipid-Lowering Therapy in Adult Participants With Homozygous Familial Hypercholesterolemia (HoFH) (MK-0859-042)
A Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled, 12-Week Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Lipid-Lowering Therapy in Adult Patients With Homozygous Familial Hypercholesterolemia (HoFH)
Status: Enrolling
Updated:  1/22/2014
Clinical Research Facility
mi
from
Winter Park, FL
Efficacy and Tolerability of Anacetrapib Added to Ongoing Lipid-Lowering Therapy in Adult Participants With Homozygous Familial Hypercholesterolemia (HoFH) (MK-0859-042)
A Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled, 12-Week Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Lipid-Lowering Therapy in Adult Patients With Homozygous Familial Hypercholesterolemia (HoFH)
Status: Enrolling
Updated: 1/22/2014
Clinical Research Facility
mi
from
Winter Park, FL
Click here to add this to my saved trials
Efficacy and Tolerability of Anacetrapib Added to Ongoing Lipid-Lowering Therapy in Adult Participants With Homozygous Familial Hypercholesterolemia (HoFH) (MK-0859-042)
A Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled, 12-Week Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Lipid-Lowering Therapy in Adult Patients With Homozygous Familial Hypercholesterolemia (HoFH)
Status: Enrolling
Updated:  1/22/2014
Clinical Research Facility
mi
from
Milkwaukee, WI
Efficacy and Tolerability of Anacetrapib Added to Ongoing Lipid-Lowering Therapy in Adult Participants With Homozygous Familial Hypercholesterolemia (HoFH) (MK-0859-042)
A Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled, 12-Week Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Lipid-Lowering Therapy in Adult Patients With Homozygous Familial Hypercholesterolemia (HoFH)
Status: Enrolling
Updated: 1/22/2014
Clinical Research Facility
mi
from
Milkwaukee, WI
Click here to add this to my saved trials